Conversely, Lawand et al.46found those who received GLP-1 receptor agonists after the same procedure had a significantly higher DVT risk (OR 3.0, 95% CI 1.5–5.9), although there was no significant difference in PE risk (OR 1.6, 95% CI 0.9–3.1). This evidence concerns the gene GLP1R and deep vein thrombosis.